Literature DB >> 26738992

The Administration of Levocabastine, a NTS2 Receptor Antagonist, Modifies Na(+), K(+)-ATPase Properties.

Alicia Gutnisky1, María Graciela López Ordieres1,2, Georgina Rodríguez de Lores Arnaiz3.   

Abstract

Neurotensin behaves as a neuromodulator or as a neurotransmitter interacting with NTS1 and NTS2 receptors. Neurotensin in vitro inhibits synaptosomal membrane Na(+), K(+)-ATPase activity. This effect is prevented by administration of SR 48692 (antagonist for NTS1 receptor). The administration of levocabastine (antagonist for NTS2 receptor) does not prevent Na(+), K(+)-ATPase inhibition by neurotensin when the enzyme is assayed with ATP as substrate. Herein levocabastine effect on Na(+), K(+)-ATPase K(+) site was explored. For this purpose, levocabastine was administered to rats and K(+)-p-nitrophenylphosphatase (K(+)-p-NPPase) activity in synaptosomal membranes and [(3)H]-ouabain binding to cerebral cortex membranes were assayed in the absence (basal) and in the presence of neurotensin. Male Wistar rats were administered with levocabastine (50 μg/kg, i.p., 30 min) or the vehicle (saline solution). Synaptosomal membranes were obtained from cerebral cortex by differential and gradient centrifugation. The activity of K(+)-p-NPPase was determined in media laking or containing ATP plus NaCl. In such phosphorylating condition enzyme behaviour resembles that observed when ATP hydrolyses is recorded. In the absence of ATP plus NaCl, K(+)-p-NPPase activity was similar for levocabastine or vehicle injected (roughly 11 μmole hydrolyzed substrate per mg protein per hour). Such value remained unaltered by the presence of 3.5 × 10(-6) M neurotensin. In the phosphorylating medium, neurotensin decreased (32 %) the enzyme activity in membranes obtained from rats injected with the vehicle but failed to alter those obtained from rats injected with levocabastine. Levocabastine administration enhanced (50 %) basal [(3)H]-ouabain binding to cerebral cortex membranes but failed to modify neurotensin inhibitory effect on this ligand binding. It is concluded that NTS2 receptor blockade modifies the properties of neuronal Na(+), K(+)-ATPase and that neurotensin effect on Na(+), K(+)-ATPase involves NTS1 receptor and -at least partially- NTS2 receptor.

Entities:  

Keywords:  Central nervous system membranes; Cerebral cortex; K+-ATPase; K+-p-Nitrophenylphosphatase; Levocabastine; NTS1 Receptor; NTS2 Receptor; Na+; Neurotensin; Synaptosomal membranes; [3H]-Ouabain binding

Mesh:

Substances:

Year:  2016        PMID: 26738992     DOI: 10.1007/s11064-015-1823-7

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  28 in total

Review 1.  Multitasking with neurotensin in the central nervous system.

Authors:  P R Dobner
Journal:  Cell Mol Life Sci       Date:  2005-09       Impact factor: 9.261

2.  Binding of divalent cation to phosphoenzyme of sodium- and potassium-transport adenosine triphosphatase.

Authors:  Y Fukushima; R L Post
Journal:  J Biol Chem       Date:  1978-10-10       Impact factor: 5.157

3.  Alternating Hemiplegia of Childhood mutations have a differential effect on Na(+),K(+)-ATPase activity and ouabain binding.

Authors:  Karl M Weigand; Muriël Messchaert; Herman G P Swarts; Frans G M Russel; Jan B Koenderink
Journal:  Biochim Biophys Acta       Date:  2014-03-12

Review 4.  Neurotensin and neurotensin receptors.

Authors:  J P Vincent; J Mazella; P Kitabgi
Journal:  Trends Pharmacol Sci       Date:  1999-07       Impact factor: 14.819

5.  Comparison of the effects of potassium on ouabain binding to native and site-directed mutants of Na,K-ATPase.

Authors:  C L Johnson; P J Schultheis; J B Lingrel; C G Johnson; E T Wallick
Journal:  Arch Biochem Biophys       Date:  1995-02-20       Impact factor: 4.013

6.  K(+)-p-nitrophenylphosphatase inhibition by neurotensin involves high affinity neurotensin receptor: influence of potassium concentration and enzyme phosphorylation.

Authors:  M G López Ordieres; G Rodríguez de Lores Arnaiz
Journal:  Regul Pept       Date:  2001-09-15

7.  In vivo studies with low doses of levocabastine and diphenhydramine, but not pyrilamine, antagonize neurotensin-mediated antinociception.

Authors:  B M Tyler; K Groshan; B Cusack; E Richelson
Journal:  Brain Res       Date:  1998-03-16       Impact factor: 3.252

8.  Neurotensin decreases high affinity [3H]-ouabain binding to cerebral cortex membranes.

Authors:  Carina Rosin; María Graciela López Ordieres; Georgina Rodríguez de Lores Arnaiz
Journal:  Regul Pept       Date:  2011-09-05

9.  Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells.

Authors:  N Vita; F Oury-Donat; P Chalon; M Guillemot; M Kaghad; A Bachy; O Thurneyssen; S Garcia; C Poinot-Chazel; P Casellas; P Keane; G Le Fur; J P Maffrand; P Soubrie; D Caput; P Ferrara
Journal:  Eur J Pharmacol       Date:  1998-11-06       Impact factor: 4.432

Review 10.  The pharmacokinetic properties of topical levocabastine. A review.

Authors:  J Heykants; A Van Peer; V Van de Velde; E Snoeck; W Meuldermans; R Woestenborghs
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.